我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
0
0 进行中
药物批准
批准总数
监管机构
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无批准数据
- The FDA issued an alert on August 27 identifying at least 30 patients who experienced adverse reactions after receiving intravenous glutathione from compounding pharmacies. - All affected pharmacies sourced their glutathione from Medisca Inc. lot 229536, which was labeled as dietary supplement grade rather than an appropriate injectable-grade ingredient. - Reported reactions include fever, chills, pain, dizziness, signs of shock, and sepsis-like symptoms, with some patients requiring hospitalization. - The agency has not approved any injectable glutathione product and continues to investigate adverse events consistent with endotoxin exposure.
